Innova Biosciences is Proud to Announce Award of ISO 9001:2008 Certification

Innova Biosciences has had its work processes accredited to internationally recognised quality management system (QMS) standards.

Cambridge, UK, January 16, 2013 - Innova Biosciences the original manufacturer and provider of high quality bioconjugation services, used primarily in research, diagnostics and the biotech industry, announced today that it has recently achieved ISO 9001:2008 certification.

Innova Biosciences has had its work processes accredited to internationally recognised quality management system (QMS) standards. In working towards this, every operational process within Innova Biosciences was analysed and challenged resulting in a more efficient and agile organisation.

Innova Biosciences Executive Director, Andy Lane stated ‘We are extremely proud to obtain ISO 9001:2008 certification, which is an important milestone in the development of the company. It is a significant achievement, but more importantly, demonstrates the commitment to a level of excellence upon which our customers in all sectors can depend. Our attention to quality and continuous improvement of our QMS is reflected in Innova obtaining this accolade.’

About Innova Biosciences Limited;
Innova Biosciences is a growing, dynamic business based in Cambridge, UK. At the core of Innova's business are Lightning-Link® and InnovaCoat® technologies that simplify the production of antibody-based reagents. The expanding portfolio of products is sold to research laboratories, pharmaceutical companies, biotechnology companies and diagnostic companies worldwide. The company is ISO 9001:2008 certified.

For more information, please see www.innovabiosciences.com

Contact:
Mathew Taylor
Director
Algorythm Solutions Ltd
10 Torkington St
Stamford, Lincolnshire PE9 2UY
+44 (0)773 403 2112
mtaylor@algorythmsolutions.com
http://www.algorythmsolutions.com

Oxford Expression Technologies Launch Innovative Virus Like Particle Expression Vector

Oxford Expression Technologies (OET), the award-winning specialist provider of baculovirus-based protein expression solutions, announce the launch of flashBACPRIME, the newest edition to the flashBAC range.

Oxford, UK, November 27, 2012 - Oxford Expression Technologies (OET), the award-winning specialist provider of baculovirus-based protein expression solutions, announce the launch of flashBACPRIME, the newest edition to the flashBAC range. The new vector is specifically designed to provide increased virus like particle yield and recovery, and also benefits from the traditional ease of use associated with the renowned flashBAC one step baculovirus expression system.

The new vector offers an innovative solution to one of the challenges of VLP production by providing scientists with enhanced recovery and yield. The performance improvement is achieved by inducing cell lysis at a very late stage of infection in Trichoplusia ni (T.ni) derived cell lines. The flashBACPRIME expression vector also offers flexibility for users, although designed for use in virus like particle production, it can also be used for cytoplasmic protein expression and production.

Passing comment, James Bernard, the CEO at Oxford Expression Technologies said, “We are pleased to announce the launch of flashBACPRIME, it represents a significant improvement in performance and we are delighted to offer these benefits to our customers” he continued, “Yield and recovery are an inherent concern with VLP production and our new technology provides scientists with a solution that addresses these concerns, we are also pleased to add another innovation to our highly successful flashBAC range.”

Oxford Expression Technologies invites anyone with an interest in baculovirus protein expression and virus like particle production to visit their website - http://oetltd.com/

Oxford Expression Technologies is a biotechnology company specializing in the use of baculovirus vectors, a eukaryotic expression system that can express a large variety of recombinant proteins. Oxford Expression Technologies provides recombinant protein expression products, services and consultancy to many global pharmaceutical companies. The Company’s proprietary flashBAC technology enables large amounts of a given protein to be produced in culture. Its internationally renowned expertise and products enable proteins to be produced faster, more easily and cost-effectively using automated and high-throughput methods compared with other baculovirus expression systems. This contributes to the development of new drugs and research targeted towards understanding how proteins work in health and disease.

The company was founded in 2007 as a result of collaboration between Oxford Brookes University and the Natural Environment Research Council to provide researchers with custom proteins for research purposes.

For Further information or an illustrative image:
Media contact - Mathew Taylor, Director, Algorythm Solutions Ltd, mobile: +44 (0)773 403 2112, email: mtaylor@algorythmsolutions.com, website: www.algorythmsolutions.com

Contact:
Mathew Taylor
Director
Algorythm Solutions Ltd
10 Torkington St
Stamford, Lincolnshire PE9 2UY
+44 (0)773 403 2112
mtaylor@algorythmsolutions.com
http://www.algorythmsolutions.com